2024 Biological License Application Approvals
This list reflects information regarding the applications as of the approval date. It is not updated with regard to applicant or application status changes. The applications are listed by date of approval.
| Tradename/Proper Name | Indication for Use | STN | Manufacturer/ License Number | Approval Date |
|---|---|---|---|---|
| SYMVESS acellular tissue engineered vessel-tyod | Indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. | 125812/0 | Humacyte Global, Inc. -----------(b)(4)--------------------(b)(4)-------- --(b)(4)-- ------(b)(4)---- ----- (b)(4)----- -------(b)(4)----- ----------(b)(4)------- ----------(b)(4)------- Lic. # 2336 | 12/19/2024 |
| RYONCIL remestemcel-L-rknd | Indicated for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older. | 125706/0 | Mesoblast, Inc. 1114 Sixth Avenue 4th Floor New York, NY 10036 Lic. # 2140 | 12/18/2024 |
| Kebilidi eladocagene exuparvovec-tneq | For treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. | 125722/0 | PTC Therapeutics, Inc. 500 Warren Corporate Center Drive Warren, New Jersey 07059 Lic. # 2168 | 11/13/2024 |
| Aucatzyl obecabtagene autoleucel | Indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). | 125813/0 | Autolus Inc. 15810 Gaither Drive, Suite 230 Gaithersburg, MD 20877 Lic. # 2339 | 11/08/2024 |
| TECELRA afamitresgene autoleucel | Indicated for treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices. | 125789/0 | Adaptimmune LLC 351 Rouse Boulevard Philadelphia, PA 19112 Lic. # 2315 | 08/01/2024 |
| CAPVAXIVE Pneumococcal 21-valent Conjugate Vaccine | Indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in individuals 18 years of age and older. | 125814/0 | Merck Sharp & Dohme LLC P.O. Box 1000 UG2D-68 North Wales, PA 19454-2505 Lic. # 0002 | 06/17/2024 |
| YIMMUGO immune globulin intravenous, human-dira | Indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age or older. | 125810/0 | Biotest AG Landsteinerstrasse 5 Dreieich, Hesse 63303 Germany Lic. # 2332 | 06/13/2024 |
| MRESVIA Respiratory Syncytial Virus Vaccine | Indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. | 125796/0 | ModernaTX, Inc. 325 Binney Street Cambridge, MA 02142 Lic. # 2256 | 05/31/2024 |
| BEQVEZ elaparvovec-dzkt | Indicated for the treatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who: currently use factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and, do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid as detected by an FDA-approved test. | 125786/0 | Pfizer, Inc. 445 Eastern Point Road Groton, CT 06340 Lic. # 2001 | 04/25/2024 |
| cobas Malaria cobas Malaria, Nucleic Acid Test for use on the cobas 6800/8800 Systems | Is a qualitative in vitro nucleic acid screening test for the direct detection of Plasmodium (P. falciparum, P. malariae, P. vivax, P. ovale and P. knowlesi) DNA and RNA in whole blood samples from individual human donors, including donors of whole blood and blood components, as well as other living donors. It is also intended for use in testing whole blood samples to screen organ and tissue donors when samples are obtained while the donor’s heart is still beating. | 125808/0 | Roche Molecular Systems, Inc. 4300 Hacienda Drive Pleasanton, CA 94588-2722 Lic. # 1636 | 03/19/2024 |
| LENMELDY atidarsagene autotemcel | Indicated for treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ) or early symptomatic early juvenile (ESEJ) metachromatic leukodystrophy (MLD). | 125758/0 | Orchard Therapeutics (Europe) Limited Orchard Therapeutics North America 101 Seaport Boulevard, 7th Floor Boston, MA 02210 Lic. # 2263 | 03/18/2024 |
| Elecsys Anti-HCV II Elecsys Anti-HCV II | An in vitro immunoassay for the qualitative detection of antibodies to hepatitis C virus (HCV) in human serum and plasma. It is intended to screen individual human donors, including volunteer donors of whole blood, blood components and source plasma. The assay is also intended to be used to screen organ, tissue and cell donors, when donor samples are obtained while the donor's heart is still beating. It is not intended for use on cord blood specimens. | 125803/0 | Roche Diagnostics 9115 Hague Road Indianapolis, IN 46250 Lic. # 2305 | 02/28/2024 |
| Elecsys Anti-HBc II Elecsys Anti-HBc II | An in vitro immunoassay for the qualitative detection of antibodies to hepatitis B core antigen (anti-HBc) in human serum and plasma. It is intended to screen individual human donors, including volunteer donors of whole blood and blood components. The assay is also intended to be used to screen organ, tissue and cell donors, when donor samples are obtained while the donor’s heart is still beating. It is not intended for use on cord blood specimens. | 125804/0 | Roche Diagnostics 9115 Hague Road Indianapolis, IN 46250 Lic. # 2305 | 02/27/2024 |
| Elecsys HBsAg II and Elecsys HBsAg II Auto Confirm Elecsys HBsAg II and Elecsys HBsAg II Auto Confirm | An in vitro immunoassay intended for the qualitative detection of hepatitis B surface antigen (HBsAg) in human serum and plasma. It is intended to screen individual human donors, including volunteer donors of whole blood, blood components and source plasma. The assay is also intended to be used to screen organ, tissue and cell donors, when donor samples are obtained while the donor’s heart is still beating. It is not intended for use on cord blood specimens. | 125802/0 | Roche Diagnostics 9115 Hague Road Indianapolis, IN 46250 Lic. # 2305 | 02/21/2024 |
| AMTAGVI Lifileucel | Indicated for treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. | 125773/0 | Iovance Biotherapeutics, Inc. 825 Industrial Road, Suite 400 San Carlos, CA 94070 Lic. # 2298 | 02/16/2024 |
| Elecsys Chagas Elecsys Chagas | An in vitro immunoassay for the qualitative detection of antibodies to Trypanosoma cruzi (T. cruzi, the causative agent of the Chagas disease) in human serum and plasma. It’s intended to screen individual human donors, including volunteer donors of whole blood and blood components. The assay is also intended to be used to screen organ, tissue and cell donors, when donor samples are obtained while the donor’s heart is still beating. It is not intended for use on cord blood specimens. | 125799/0 | Roche Diagnostics 9115 Hague Road Indianapolis, IN 46250 Lic. # 2305 | 02/05/2024 |
| Source Plasma | Indicated for further manufacturing of injectable products. | 125783/0 | Life Plasma, Inc. 5438 Perkiomen Avenue Reading, PA 19606 Lic. # 2311 | 01/30/2024 |
| Source Plasma | Indicated for further manufacturing of injectable products. | 125783/0 | Life Plasma, Inc. 5438 Perkiomen Avenue Reading, PA 19606 Lic. # 2311 | 01/30/2024 |
| CASGEVY Exagamglogene autotemcel | Indicated the treatment of patients aged 12 years and older with transfusion-dependent ß-thalassemia (TDT). | 125785/0 | Vertex Pharmaceuticals Inc 50 Northern Avenue Boston, MA 02210 Lic. # 2279 | 01/16/2024 |